Dr. Mark Saunders received his degree in Biochemistry from The University of Exeter and his PhD from the London School of Pharmacy. He is a tested professional with scientific and leadership skills in the pharmaceutical industry who has spent nearly 20 years working in and leading various contract research and development organizations. After completing his PhD, Mark joined a spin-out CRO providing outsourced support for physiochemical properties testing for NCEs. The company quickly grew and Mark oversaw the implementation of both the solid-form screening and formulation groups, including the Phase I/II clinical manufacturing for oral and inhaled drug products. After the business was acquired in 2007, Mark immediately went on to found Kuecept Ltd, an early-stage CRO specializing in designing bespoke preclinical and early-clinical formulations for drugs that exhibit complex bioavailability barriers (oral, parenteral and inhaled RoAs). Since establishing the business in 2007, the company’s technical expertise was globally recognized by over 100 leading pharma and biotech organizations and in April 2016, Kuecept Ltd was acquired by Aptuit LLC. After 2 years supporting the integration of the group into the wider Aptuit business, Mark left to set up his own consulting service, P2C Pharma Ltd. In addition to his consultancy role, Mark is also a Strategic Advisor at Fluid Pharma, a technology company providing drug delivery solutions for taste-masking and GI targeting for pediatric and geriatric patients as well as being a Director at Relevo Ltd, a technology disruptor company providing digital respiratory healthcare devices to aid patient compliance in medication adherence.